万邦医药
(301520)
| 流通市值：20.13亿 | | | 总市值：53.68亿 |
| 流通股本：3493.84万 | | | 总股本：9317.14万 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 184,230,296.31 | 87,757,664.33 | 30,541,322 | 274,180,232.26 |
| 营业收入 | 184,230,296.31 | 87,757,664.33 | 30,541,322 | 274,180,232.26 |
| 利息收入 | 0 | - | 0 | 0 |
| 已赚保费 | 0 | - | 0 | 0 |
| 手续费及佣金收入 | 0 | - | 0 | 0 |
| 二、营业总成本 | 200,339,891.82 | 104,892,117.23 | 40,632,188.33 | 265,143,198.25 |
| 营业成本 | 137,543,270.22 | 71,612,026.83 | 25,885,199.43 | 203,170,661.76 |
| 利息支出 | 0 | - | 0 | 0 |
| 手续费及佣金支出 | 0 | - | 0 | 0 |
| 退保金 | 0 | - | 0 | 0 |
| 赔付支出净额 | 0 | - | 0 | 0 |
| 提取保险合同准备金净额 | 0 | - | 0 | 0 |
| 保单红利支出 | 0 | - | 0 | 0 |
| 分保费用 | 0 | - | 0 | 0 |
| 税金及附加 | 1,631,221.88 | 974,977.07 | 315,300.06 | 1,611,082.66 |
| 销售费用 | 8,672,187.15 | 4,397,757.45 | 1,763,376.35 | 5,822,278.66 |
| 管理费用 | 22,650,462.19 | 12,398,724.97 | 4,723,614.48 | 22,607,587.91 |
| 研发费用 | 30,078,876.5 | 15,754,626.35 | 8,054,159.67 | 32,931,809.85 |
| 财务费用 | -236,126.12 | -245,995.44 | -109,461.66 | -1,000,222.59 |
| 其中:利息费用 | 72,671.54 | 0 | 0 | - |
| 其中:利息收入 | 330,886.78 | 253,850.52 | 115,137.62 | 1,021,521.88 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,098,925.37 | 7,703,782.34 | 5,992,624.03 | 18,983,525.97 |
| 加:投资收益 | 11,943,665.38 | 7,933,275.38 | 1,162,395.73 | 12,933,909.07 |
| 净敞口套期收益 | 0 | - | 0 | 0 |
| 汇兑收益 | 0 | - | 0 | 0 |
| 资产处置收益 | -7,038.83 | -7,038.83 | 0 | -55,767.7 |
| 资产减值损失(新) | 473,296.47 | 617,633.07 | 479,612.05 | -2,340,086.16 |
| 信用减值损失(新) | -6,166,526.38 | -3,646,463.27 | -195,940.71 | -4,788,193.39 |
| 其他收益 | 2,876,378.1 | 1,385,784.83 | 847,941.39 | 7,695,111.98 |
| 四、营业利润 | 109,104.6 | -3,147,479.38 | -1,804,233.84 | 41,465,533.78 |
| 加:营业外收入 | 443.26 | 294.77 | 0 | 7,066.53 |
| 减:营业外支出 | 523,045.68 | 76,482.23 | 1.2 | 5,619,461.89 |
| 五、利润总额 | -413,497.82 | -3,223,666.84 | -1,804,235.04 | 35,853,138.42 |
| 减:所得税费用 | -4,438,091.34 | -3,361,659.71 | -1,542,452.88 | -581,315.15 |
| 六、净利润 | 4,024,593.52 | 137,992.87 | -261,782.16 | 36,434,453.57 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 4,024,593.52 | 137,992.87 | -261,782.16 | 36,434,453.57 |
| 终止经营净利润 | 0 | - | 0 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 572,346.14 | 137,992.87 | -261,782.16 | 36,434,453.57 |
| 少数股东损益 | 3,452,247.38 | - | - | - |
| 扣除非经常损益后的净利润 | -16,338,503.05 | -13,430,876.92 | -6,625,378.24 | 8,932,974.8 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | 0 | 0 | 0.55 |
| (二)稀释每股收益 | 0.01 | 0 | 0 | 0.55 |
| 八、其他综合收益 | 0 | - | - | 0 |
| 归属于母公司股东的其他综合收益 | 0 | - | - | - |
| 九、综合收益总额 | 4,024,593.52 | 137,992.87 | -261,782.16 | 36,434,453.57 |
| 归属于母公司股东的综合收益总额 | 572,346.14 | 137,992.87 | -261,782.16 | 36,434,453.57 |
| 归属于少数股东的综合收益总额 | 3,452,247.38 | - | - | - |
| 公告日期 | 2026-10-30 | 2026-08-29 | 2026-04-23 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |